Non-Small Cell Lung Cancer
Conditions
Keywords
Non small cell lung cancer, Advanced, Inoperable, taxanes, carboplatin, multi-drug resistance
Brief summary
Multiple Drug Resistance is the phenomena whereby cells become resistant to a variety of drugs with different mechanisms of action. Drug resistance remains a significant impediment to successful cancer chemotherapy inhibitors have been developed and are currently in clinical trials. CBT-1 is a natural product currently in clinical trials as an inhibitor
Detailed description
Lung cancer has the highest incidence and prevalence among cancers in the world and remains the leading cause of cancer-related deaths in Western countries. One-year survival of patients with best supportive care remains low. Non-small-cell lung cancer accounts for almost 85% of all lung cancer cases. Approximately 70% of patients have locally advanced or metastatic disease at presentation and are not candidates for surgery.
Interventions
DRUGCBT-1
(50 mg caps) 500 mg/m2/day x 7 + paclitaxel 135 mg/m2 + carboplatin AUC 6
OTHERPlacebo
(50 mg caps) 500 mg/m2/day x 7 + paclitaxel 135 mg/m2 + carboplatin AUC 6
Sponsors
CBA Research
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* histological confirmed diagnosis of NSCLC * advanced inoperable NSCLC * have adequate renal function, serum creatinine \<2.0 mg/dL or 24 hour creatinine clearance \> 50mL/minute * have adequate liver function defined as SGOT \<4 times the upper limit of normal (ULN) and bilirubin \<2.0 mg/dL * have calcium \<11.0 mg/dL and albumin \>2.0g/dL * have adequate bone marrow reserve defined as granulocyte count \>1,500/mm3, hemoglobin \>10.0 g/dL and platelets \>100,000/mm3 * if female and of child-bearing potential, agree to use one of the following methods of birth control: oral contraceptives, barrier with spermicide, intrauterine progesterone contraceptive system, levonorgestrel implant, medroxyprogesterone acetate contraceptive injection, complete abstinence from sexual intercourse
Exclusion criteria
* have previously received taxanes, platinums, vinca alkaloids, anthracyclines, epipodophyllotoxins or CBT-1 * have known or suspected hypersensitivity to platinum containing compounds, taxanes, polyoxyethylated castor oil, or mannitol * have significant central nervous system disease, including history of seizures within last 3 months or psychiatric history which would impair the ability to give informed consent or prevent compliance with protocol requirements * be eligible for curative surgery or radiotherapy. * must not have a diagnosis and/or treatment in the past 5 years of any malignancy other than NSCLC or basal cell carcinoma of the skin * be pregnant or nursing * have a history of significant coronary artery disease, cardiac arrhythmias requiring treatment, history of other cardiac disease or other cardiac anomalies determined by ECG which in the judgment of the investigator would compromise the patient's ability to tolerate the therapy * have ongoing serious infections that require parenteral antibiotics * have clinically significant bleeding disorders * have solid organ allograft * have significant intercurrent disease * have bleeding peptic ulcer disease * have participated in any experimental study within 2 months preceding enrollment * be using a medication that could interact adversely with CBT-1, paclitaxel, or carboplatin. Medications include:aminoglycoside antibiotics, Prilosec, Losec, Zantac
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival | every month for first 6 months off study, then every 2-3 months for the next year, then every 6 months thereafter |
Secondary
| Measure | Time frame |
|---|---|
| Time to Progression | each month for the first 6 months off study, then every 2-3 months for the next year, then every 6 months thereafter. |
| Response Rates | every 2-3 months following completion of therapy until disease progression |
| Progression Free Survival | every month for first 6 months off study, then every 2-3 months for next year, then every 6 months thereafter. |
Countries
United States
Outcome results
None listed